AxoGen, Inc. (NASDAQ:AXGN) Director Jamie Mark Grooms sold 38,405 shares of AxoGen stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $26.35, for a total transaction of $1,011,971.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jamie Mark Grooms also recently made the following trade(s):

  • On Wednesday, December 6th, Jamie Mark Grooms sold 21,290 shares of AxoGen stock. The stock was sold at an average price of $26.22, for a total transaction of $558,223.80.
  • On Friday, December 8th, Jamie Mark Grooms sold 84,295 shares of AxoGen stock. The stock was sold at an average price of $26.38, for a total transaction of $2,223,702.10.

Shares of AxoGen, Inc. (NASDAQ:AXGN) opened at $27.50 on Friday. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55. AxoGen, Inc. has a 12-month low of $8.35 and a 12-month high of $27.75.

AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The business had revenue of $16.05 million for the quarter, compared to analysts’ expectations of $15.55 million. AxoGen’s quarterly revenue was up 43.2% compared to the same quarter last year. equities research analysts expect that AxoGen, Inc. will post -0.31 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AXGN. Bank of New York Mellon Corp boosted its position in shares of AxoGen by 293.9% in the third quarter. Bank of New York Mellon Corp now owns 631,563 shares of the medical equipment provider’s stock worth $12,222,000 after acquiring an additional 471,209 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of AxoGen by 238.7% in the second quarter. Russell Investments Group Ltd. now owns 611,678 shares of the medical equipment provider’s stock worth $10,245,000 after acquiring an additional 431,057 shares during the last quarter. Castleark Management LLC acquired a new stake in shares of AxoGen in the second quarter worth approximately $5,426,000. Bamco Inc. NY acquired a new stake in shares of AxoGen in the third quarter worth approximately $3,443,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of AxoGen in the first quarter worth approximately $1,473,000. 66.00% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently commented on AXGN. Leerink Swann reiterated an “outperform” rating and set a $23.00 price target (up from $22.00) on shares of AxoGen in a report on Saturday, September 30th. Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 price target on shares of AxoGen in a report on Monday, August 21st. Wedbush reiterated a “buy” rating and set a $27.00 price target (up from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. Lake Street Capital lifted their price target on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 21st. Finally, Jefferies Group began coverage on shares of AxoGen in a report on Thursday, November 30th. They set a “buy” rating and a $35.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $26.17.

COPYRIGHT VIOLATION WARNING: “Insider Selling: AxoGen, Inc. (AXGN) Director Sells $1,011,971.75 in Stock” was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.watchlistnews.com/insider-selling-axogen-inc-axgn-director-sells-1011971-75-in-stock/1767437.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.